APA (7th ed.) Citation

Mozessohn, L., & Buckstein, R. (2025). Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes? Ferrata Storti Foundation.

Chicago Style (17th ed.) Citation

Mozessohn, Lee, and Rena Buckstein. Should We Move Past Erythropoietin-stimulating Agent Monotherapy in Lower-risk Myelodysplastic Syndromes? Ferrata Storti Foundation, 2025.

MLA (9th ed.) Citation

Mozessohn, Lee, and Rena Buckstein. Should We Move Past Erythropoietin-stimulating Agent Monotherapy in Lower-risk Myelodysplastic Syndromes? Ferrata Storti Foundation, 2025.

Warning: These citations may not always be 100% accurate.